Intraperitoneal Cisplatin and Carboplatin in the Management of Ovarian Cancer

  • Maurie Markman

Abstract

In the early 1980’s, investigators at a number of institutions began to explore the intraperitoneal administration of cisplatin as therapy of ovarian cancer. Several factors provide strong support for these initial and subsequent clinical trials, including:
  1. 1.

    Ovarian cancer is a malignancy which tends to remain localized to the peritoneal cavity for most of its natural history (1,2).

     
  2. 2.

    Pharmacokinetic modeling studies have suggested that following intraperitoneal drug delivery it is possible to expose tumor within the cavity to significantly higher drug concentrations than possible following systemic administration (3).

     
  3. 3.

    Cisplatin is the single most active antineoplastic agent in the management of ovarian cancer (4).

     
  4. 4.

    Experimental data and retrospective evaluation of clinical trials have suggested that there is a relatively steep dose response curve for cisplatin against ovarian cancer (5,6). In addition, pre-clinical evaluation has demonstrated that resistance to cisplatin is often only “relative” with 2–4 fold increases in drug concentrations being capable of overcoming resistance in in vitro systems (7,8).

     
  5. 5.

    Unfortunately, the dose of cisplatin which can be administered systemically is limited by both the nephrotoxic and, most importantly, neurotoxic effects of the agent (9). Phase 1 trials of intraperitoneal cisplatin in ovarian cancer

     

Keywords

Ovarian Cancer Intraperitoneal Chemotherapy Advanced Ovarian Cancer Intraperitoneal Route Refractory Ovarian Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    E.B. Obel, A comparative study of patients with cancer of the ovary who survived more or less than 10 years. Acta. Obstet. Gynecol. Scand. 55:429 (1976).PubMedCrossRefGoogle Scholar
  2. 2.
    F. Bergman, Carcinoma of the ovary: A clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta. Obstet. Et. Gynec. Scandinav. 45:211 (1966).CrossRefGoogle Scholar
  3. 3.
    R.L. Dedrick, C.E. Myers, P.M. Bungay, and V.T. DeVita, Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer, Cancer Treat. Rep., 62:1 (1978).PubMedGoogle Scholar
  4. 4.
    R.F. Ozols, and R.C. Young, Ovarian Cancer, Curr. Prob. Cancer, 11:59 (1987).CrossRefGoogle Scholar
  5. 5.
    D.S. Alberts, L. Young, N. Mason and S.E. Salmon, In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration, Semin. Oncol, 12(3)(Suppl 4):38 (1985).PubMedGoogle Scholar
  6. 6.
    L. Levin, and W.M. Hryniuk, Dose intensity analysis of chemotherapy regimens in ovarian cancer, J. Clin. Oncol., 5:756, (1987).PubMedGoogle Scholar
  7. 7.
    R.F. Ozols, Pharmacologic reversal of drug resistance in ovarian cancer, Semin. Oncol., 12(3)(Suppl 4):7, (1985).PubMedGoogle Scholar
  8. 8.
    P.A. Andrews, S. Velury, S.C. Mann, and S.B. Howell, Cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells, Cancer Res. 48:68, (1988).PubMedGoogle Scholar
  9. 9.
    R.F. Ozols, B.J. Corden, J. Jacob, M.N. Wesley, Y. Ostchega, and R.C. Young, High-dose cisplatin in hypertonic saline, Ann. Intern. Med. 100:19, (1984).PubMedCrossRefGoogle Scholar
  10. 10.
    S.B. Howell, C.E. Pfeifle, W.E. Wung, R.A. Olshen, W.E. Lucas, J.L. Yon, and M. Green, Intraperitoneal cisplatin with systemic thiosulfate protection, Ann. Intern. Med., 97:845 (1982).PubMedCrossRefGoogle Scholar
  11. 11.
    E.S. Casper, D.P. Kelsen, N.W. Alcock, and J.L. Lewis, Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the i.v. route. Cancer Treat. Rep. 67:235 (1983).PubMedGoogle Scholar
  12. 12.
    R.G. Pretorius, N.F. Hacker, J.S. Berek, L.C. Ford, J.D. Hoeschele, T.A. Butler, and L.D. Lagasse, Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat. Rep. 67:1085 (1983).PubMedGoogle Scholar
  13. 13.
    M. Markman, S. Cleary, S.B. Howell, and W.E. Lucas, Complications of extensive adhesion formation following intraperitoneal chemotherapy Surg. Gynecol. Obstet. 162:445 (1986).Google Scholar
  14. 14.
    K.K. Chen, and C.L. Rose, Nitrite and thiosulfate therapy in cyanide poisoning, JAMA 149:113, (1952).CrossRefGoogle Scholar
  15. 15.
    S.B. Howell, and R. Taetle, Effect of sodium thiosulfate on cis-dichlorodiammineplatinum (II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat. Rep. 64:611 (1980).PubMedGoogle Scholar
  16. 16.
    M. Shea, J. Koziol, and S.B. Howell, Kinetics of sodium thiosulfate, a cisplatin neutralizer, Clin Pharmacol. Ther., 35:419 (1984).PubMedCrossRefGoogle Scholar
  17. 17.
    M. Markman, S. Howell, W.E. Lucas, C.E. Pfeifle, and M.R. Green, Combination intraperitoneal chemotherapy with cisplatin, cytarabine. and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J. Clin. Oncol.. 2:1321, 1984.PubMedGoogle Scholar
  18. 18.
    M. Markman, S. Howell, S. Cleary, and W.E. Lucas. Intraperitoneal chemotherapy with high dose cisplatin and cytarabine for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J. Clin. Oncol. 3:925, 1985.PubMedGoogle Scholar
  19. 19.
    M. Markman, S. Cleary, W.E. Lucas, R. Weiss, and S.B. Howell, Intraperitoneal chemotherapy employing a regimen of cisplatin, cytarabine and bleomycin, Cancer Treat. Rep., 70:755 (1986).PubMedGoogle Scholar
  20. 20.
    S. Zimm, S. Cleary, W.E. Lucas, R.J. Weiss, M. Markman, P.A. Andrews, M.A. Scheifler, C. Horton, and S.B. Howell, Phase 1/pharmacokinetic study of intraperitoneal cisplatin and etoposide, Cancer Res., 47:1712 (1987).PubMedGoogle Scholar
  21. 21.
    M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, S. Rubin, W. Jones, L. Almadrones, and J.L. Lewis Jr., Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, J. Clin. Oncol., (in press) (1990).Google Scholar
  22. 22.
    M.E. Gore, I. Fryatt, E. Wiltshaw, and T. Dawson. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol.. 36:207, 1990.PubMedCrossRefGoogle Scholar
  23. 23.
    G. Los, P.A. Mutsaers, W.J.F. van der Vijgh, G.S. Baldew, P.W. de Graaf, and J.G. McVie, Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy, Cancer Res. 49:3380 (1989).PubMedGoogle Scholar
  24. 24.
    M. Markman, T. Hakes, B. Reichman, W. Hoskins, S. Rubin, and J.L. Lewis, Jr, Intraperitoneal versus intravenous cisplatin-based therapy in small-volume residual refractory ovarian cancer: evidence supporting an advantage for local drug delivery. Reg. Cancer Treat. 3:10 (1990).Google Scholar
  25. 25.
    D.S. Alberts, and N. Mason-Liddil, Carboplatin in the treatment of ovarian cancer. Semin. Oncol., 16(2)(Suppl 5):19, (1989).PubMedGoogle Scholar
  26. 26.
    M.W. DeGregorio, B.L. Lum, W.M. Holleran, B.J. Wilbur, and B.I. Sikic, Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase 1 study of the Northern California Oncology Group, Cancer Chemother. Pharmacol., 18:235 (1986).Google Scholar
  27. 27.
    F. Elferink, W.J.F. van der Vijgh, I. Klein, W.W. ten Bokkel Huinink, R. Dubbelman, and J.G. McVie, Pharmacokinetics of carboplatin after intraperitoneal administration, Cancer Chemother. Pharmacol., 21:57 (1988).PubMedCrossRefGoogle Scholar
  28. 28.
    P. Pfeiffer, O. Bennedbaek, and K. Bertelsen, Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer, Gynecol. Oncol. 36:306 (1990).PubMedCrossRefGoogle Scholar
  29. 29.
    J.L. Speyer, U. Beller, N. Colombo, J. Sorich, J.C. Wernz, H. Hochster, M. Green, R. Porges, F.M. Muggia, R. Canetta, and E.M. Beckman, Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy, J. Clin. Oncol., 8:1335 (1990).PubMedGoogle Scholar
  30. 30.
    T.C. Shea, J.R. Mason, B. Newton, A.M. Storniolo, R. Taetle, and M.R. Green, High dose carboplatin with recombinant human granulocyte-macrophage colony stimulating factor: a phase 1 study, Proc. Am. Soc. Clin. Oncol., 9:286, (1990).Google Scholar
  31. 31.
    G. Los, and J. McVie, Carboplatin an alternative for intraperitoneal cisplatin treatment in cancers restricted to the peritoneal cavity? Proc. Am. Soc. Clin. Oncol.. 9:157 (1990).Google Scholar
  32. 32.
    S.B. Howell, S. Kirmani, W.E. Lucas, S. Zimm, R. Goel, S. Kim, M.C. Horton, L. McVey, J. Morris, and R.J. Weiss. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer. J. Clin. Oncol.. 8:137, 1990.PubMedGoogle Scholar
  33. 33.
    T. Hakes, M. Markman, B. Reichman, W. Hoskins, W. Jones, S. Rubin, L. Almadrones, and J.L. Lewis. High intensity intravenous cyclophosphamide/cisplatin and intraperitoneal cisplatin for advanced ovarian cancer. Proc. Am. Soc. Clin. Oncol.. 8:84, 1989.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Maurie Markman
    • 1
  1. 1.Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations